Home Biological science Jerome Canada Research Institute for Advanced Biological Sciences and Technology Discovers BCL2A1 Regulator Gene for Treatment of Triple-Negative Breast Cancer | national

Jerome Canada Research Institute for Advanced Biological Sciences and Technology Discovers BCL2A1 Regulator Gene for Treatment of Triple-Negative Breast Cancer | national


TAKOMA PARK, Md.–(BUSINESS WIRE)–March 15, 2022–

The Jerome Canada Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), today announced that its recent paper, “BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC)”, was published in Scientific Reports, a Nature Portfolio journal. This new discovery marks a significant advance in cold plasma technology for the treatment of cancer.

JCRI-ABTS scientists have demonstrated that a combination of Canady Helios™ Cold Plasma (CHCP) and anti-BCL2A1 treatment may be beneficial and provide a new treatment option for triple-negative breast cancer and other tumor cancers solid.

BCL2A1 expression plays an important role in cell survival after CHCP treatment in breast cancer cells and is potentially regulated by TNF-alpha. Silencing BCL2A1 by siRNA treatment or by downregulating its expression by CPI203 treatment in combination with CHCP significantly increases the potency of CHCP treatment.

Breast cancer is the leading cause of cancer death in women. Triple negative breast cancer (TNBC) has a very poor prognosis and frequent relapses occur early compared to other cancer subtypes. CHCP shows promise as a therapy for a variety of poor prognosis breast cancer types and BCL2A1 could be a potential companion diagnostic biomarker.

According to Jerome Canady, MD, Scientific Director, “We investigated the expression profile of 48 apoptotic gene markers and 35 oxidative markers after CHCP treatment in this study, and we are pleased to report the cell death induced by Canady Helios Cold Plasma in TNBC cell lines. ”.

Dr. Taisen Zhuang, USMI CTO, said, “These outstanding results, discovered by our scientists, provide a solid theoretical foundation and will drive the commercialization process for Cold Plasma Oncotherapeutics™. Patients with TNBC will benefit from our cold plasma technology in the near future.”

JCRI-ABTS and its sister company USMI recently successfully completed a Phase 1 clinical trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and Stage 4 solid tumors (FDA IDE #G190195).


JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on plasma oncotherapy (a novel cancer treatment modality) using Canady Helios™ cold plasma to study the potential of cold atmospheric plasma to selectively treat cancer

About American Medical Innovations

US Medical Innovations, LLC (USMI) is a privately held US biomedical device company and a wholly owned subsidiary of US Patent Innovations, LLC. USMI focuses on the development of innovative and affordable plasma and robotic electrosurgical devices and strives to develop innovative devices in the field of plasma technology for cancer eradication.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220315005579/en/

CONTACT: US Medical Innovations, LLC

Kenniah Chestnut, Esq. Vice President of Corporate Affairs






SOURCE: American Medical Innovations, LLC

Copyright BusinessWire 2022.

PUBLISHED: 03/15/2022 09:30/DISC: 03/15/2022 09:32


Copyright BusinessWire 2022.